Cargando…

Boosting subdominant neutralizing antibody responses with a computationally designed epitope-focused immunogen

Throughout the last several decades, vaccination has been key to prevent and eradicate infectious diseases. However, many pathogens (e.g., respiratory syncytial virus [RSV], influenza, dengue, and others) have resisted vaccine development efforts, largely because of the failure to induce potent anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Sesterhenn, Fabian, Galloux, Marie, Vollers, Sabrina S., Csepregi, Lucia, Yang, Che, Descamps, Delphyne, Bonet, Jaume, Friedensohn, Simon, Gainza, Pablo, Corthésy, Patricia, Chen, Man, Rosset, Stéphane, Rameix-Welti, Marie-Anne, Éléouët, Jean-François, Reddy, Sai T., Graham, Barney S., Riffault, Sabine, Correia, Bruno E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400402/
https://www.ncbi.nlm.nih.gov/pubmed/30789898
http://dx.doi.org/10.1371/journal.pbio.3000164
Descripción
Sumario:Throughout the last several decades, vaccination has been key to prevent and eradicate infectious diseases. However, many pathogens (e.g., respiratory syncytial virus [RSV], influenza, dengue, and others) have resisted vaccine development efforts, largely because of the failure to induce potent antibody responses targeting conserved epitopes. Deep profiling of human B cells often reveals potent neutralizing antibodies that emerge from natural infection, but these specificities are generally subdominant (i.e., are present in low titers). A major challenge for next-generation vaccines is to overcome established immunodominance hierarchies and focus antibody responses on crucial neutralization epitopes. Here, we show that a computationally designed epitope-focused immunogen presenting a single RSV neutralization epitope elicits superior epitope-specific responses compared to the viral fusion protein. In addition, the epitope-focused immunogen efficiently boosts antibodies targeting the palivizumab epitope, resulting in enhanced neutralization. Overall, we show that epitope-focused immunogens can boost subdominant neutralizing antibody responses in vivo and reshape established antibody hierarchies.